231 related articles for article (PubMed ID: 9882028)
1. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
[TBL] [Abstract][Full Text] [Related]
2. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
[TBL] [Abstract][Full Text] [Related]
3. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
5. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
6. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
7. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Wang Y; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 May; 2016(5):CD000544. PubMed ID: 27158764
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Loftus EV; Kane SV; Bjorkman D
Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
[TBL] [Abstract][Full Text] [Related]
9. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Muijsers RB; Goa KL
Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
Rahimi R; Nikfar S; Rezaie A; Abdollahi M
Dig Dis Sci; 2009 Apr; 54(4):712-21. PubMed ID: 18683049
[TBL] [Abstract][Full Text] [Related]
11. Balsalazide.
Prakash A; Spencer CM
Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
[TBL] [Abstract][Full Text] [Related]
12. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
13. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
[TBL] [Abstract][Full Text] [Related]
14. Review article: balsalazide therapy in ulcerative colitis.
Ragunath K; Williams JG
Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
[TBL] [Abstract][Full Text] [Related]
15. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
[TBL] [Abstract][Full Text] [Related]
16. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
17. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
Green JR; Swan CH; Rowlinson A; Gibson JA; Brown P; Kerr GD; Swarbrick ET; Thornton P
Aliment Pharmacol Ther; 1992 Oct; 6(5):647-52. PubMed ID: 1420754
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
Nikfar S; Rahimi R; Rezaie A; Abdollahi M
Dig Dis Sci; 2009 Jun; 54(6):1157-70. PubMed ID: 18770034
[TBL] [Abstract][Full Text] [Related]
19. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
Giaffer MH; Holdsworth CD; Lennard-Jones JE; Rodrigues CA; McIntyre PB; Manjunatha S; Baron JH; Barrison IG; Polson RJ; Hoare AM
Aliment Pharmacol Ther; 1992 Aug; 6(4):479-85. PubMed ID: 1358234
[TBL] [Abstract][Full Text] [Related]
20. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
